A new public-private partnership between the National Institutes of
Health and the pharmaceutical industry is establishing a program to hasten
discovery of biological markers for osteoarthritis.
Biological specimens, images, and clinical data will be collected from
men and women aged 45 years or older at risk for developing osteoarthritis
or those with early stages of the disease. Scientists hope to identify new
biological markers that indicate changes in bone or cartilage, which may help
in the diagnosis and treatment of osteoarthritis.
Hampton T. Osteoarthritis Initiative. JAMA. 2004;291(16):1951. doi:10.1001/jama.291.16.1951-a